- Home
- Publications
- Publication Search
- Publication Details
Title
Navigating adalimumab biosimilars: an expert opinion
Authors
Keywords
-
Journal
Journal of Comparative Effectiveness Research
Volume 12, Issue 11, Pages -
Publisher
Becaris Publishing Limited
Online
2023-10-19
DOI
10.57264/cer-2023-0117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
- (2023) Beatriz Gros et al. United European Gastroenterology Journal
- A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program
- (2022) Kristin Karlsdottir et al. Frontiers in Medicine
- Real-World Outcomes Following Switching from Anti-TNF Reference Products to Biosimilars for the Treatment of Psoriasis
- (2022) Rachel C. Ruda et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Patient knowledge about biosimilars and satisfaction with the education provided by rheumatologists or nurse specialists in a biosimilar multiswitch scenario – The perception study
- (2022) Sabina Gall et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Overview of Humira® Biosimilars: Current European Landscape and Future Implications
- (2021) Jill Coghlan et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis
- (2021) Daniel E Furst et al. RHEUMATOLOGY
- Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study
- (2021) Steven R. Feldman et al. BIODRUGS
- Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
- (2021) Eduardo Mysler et al. DRUGS
- Classification and mitigation of negative injection experiences with biologic medications
- (2020) Jennifer M. Fernandez et al. Dermatologic Therapy
- P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience
- (2020) D Rosembert et al. Journal of Crohns & Colitis
- PF-06410293: An Adalimumab Biosimilar
- (2020) Arnold Lee et al. BIODRUGS
- Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
- (2020) Anja St Clair-Jones et al. Rheumatology and Therapy
- Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
- (2019) Salvatore Bellinvia et al. BIODRUGS
- AURIEL ‐PsO: A randomised, double‐blind Phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
- (2019) J. Hercogová et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of pain associated with the subcutaneous administration of adalimumab
- (2019) Cristina Gely et al. Gastroenterologia y Hepatologia
- The Clinical Implications of Nocebo Effects for Biosimilar Therapy
- (2019) Luana Colloca et al. Frontiers in Pharmacology
- Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases
- (2019) Michaël Somers et al. Journal of Crohns & Colitis
- Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis
- (2018) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Injectability as a function of viscosity and dosing materials for subcutaneous administration
- (2018) Russell P. Watt et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Role of Buffers in Protein Formulations
- (2017) Teddy J. Zbacnik et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
- (2017) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The road from development to approval: evaluating the body of evidence to confirm biosimilarity
- (2017) Paul Declerck et al. RHEUMATOLOGY
- Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
- (2017) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries
- (2016) Roman Mathaes et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Underappreciated medication contraindication
- (2010) Alicia J. Zbehlik et al. ARTHRITIS CARE & RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now